Yano K, Iijima K, Sao H, Kobayashi M
Department of Hematology, Hamamatsu Medical Center, Japan.
Int J Hematol. 1996 Oct;64(3-4):267-70. doi: 10.1016/0925-5710(96)00486-0.
A patient with chronic myelogenous leukemia (CML) in chronic phase (CP) had been treated with a syngeneic bone marrow transplantation (BMT). Cytogenetic remission was confirmed 3 months later. One year after transplantation, hematological remission persisted while cytogenetic analysis revealed a recurrence of Philadelphia chromosome (Ph1). Five months later, we began treatment with human lymphoblastoid interferon (HLBI), a natural interferon (IFN)-alpha. Fourteen months after initiation of HLBI administration, cytogenetic analysis of the patient's bone marrow showed disappearance of Ph1 positive cells. One year after confirming cytogenetic remission, the absence of bcr-abl transcripts by polymerase chain reaction (PCR) assay indicated molecular remission. IFN therapy appears to be the first choice of treatment for cytogenetic relapse after syngeneic BMT. The efficacy of IFN appears to be due to an anti-malignancy effect, not to graft versus leukemia (GVL) effect.
一名处于慢性期（CP）的慢性粒细胞白血病（CML）患者接受了同基因骨髓移植（BMT）治疗。3个月后证实细胞遗传学缓解。移植后1年，血液学缓解持续存在，但细胞遗传学分析显示费城染色体（Ph1）复发。5个月后，我们开始用人淋巴母细胞干扰素（HLBI）进行治疗，HLBI是一种天然α干扰素（IFN）。在开始使用HLBI治疗14个月后，对患者骨髓进行的细胞遗传学分析显示Ph1阳性细胞消失。在确认细胞遗传学缓解1年后，通过聚合酶链反应（PCR）检测未发现bcr-abl转录本，表明达到分子学缓解。IFN治疗似乎是同基因BMT后细胞遗传学复发的首选治疗方法。IFN的疗效似乎归因于抗恶性肿瘤作用，而非移植物抗白血病（GVL）作用。
